Targeted therapy in pediatric malignancies treatment: Pediatric Oncology and Haematology Research Institute experience
- 作者: Valiev T1, Levashov A1, Batmanova N1, Senzhapova E1, Turupaev K2, Tomchik U3, Aleskerova G1
-
隶属关系:
- Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation
- A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
- N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
- 期: 卷 19, 编号 2 (2017)
- 页面: 54-60
- 栏目: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27149
- ID: 27149
如何引用文章
全文:
详细
作者简介
T Valiev
Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federation
Email: timurvaliev@mail.ru
д-р мед. наук, ст. науч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ «РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24
A Levashov
Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federationнауч. сотр. отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии «ФГБУ РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24
N Batmanova
Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federationврач отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ «РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24
E Senzhapova
Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federationнауч. сотр. отд-ния опухолей опорно-двигательного аппарата НИИ детской онкологии и гематологии ФГБУ «РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24
K Turupaev
A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation
Email: kir-turupaev@yandex.ru
студент 5-го курса лечебного фак-та ФГБОУ ВО «МГМСУ им. А.И.Евдокимова» 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
U Tomchik
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Email: vip_uv@mail.ru
студентка 5-го курса педиатрического фак-та ФГБОУ ВО «РНИМУ им. Н.И.Пирогова» 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
G Aleskerova
Pediatric Oncology and Haematology Research Institute of N.N.Blokhin Russian Cancer Reseach Center of the Ministry of Health of the Russian Federationаспирантка отд-ния химиотерапии гемобластозов НИИ детской онкологии и гематологии ФГБУ «РОНЦ им. Н.Н.Блохина» 127273, Russian Federation, Moscow, Kashirskoe sh., d. 24
参考
- Программное лечение заболеваний системы крови. Под ред. В.Г.Савченко. М., 2012.
- Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). М., 2010.
- Руководство по химиотерапии опухолевых заболеваний. Под ред. Н.И.Переводчиковой. М., 2011.
- Состояние онкологической помощи населению России в 2015 году. Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М., 2016.
- Валиев Т.Т., Левашов А.С., Сенжапова Э.Р. Таргетные препараты в детской онкологии. Онкопедиатрия. 2016; 3 (1): 8-15.
- Goldman S, Smith L, Anderson J.R et al. Outcome of advanced stage (III/IV) intermediate - risk patients with mature B-NHL using rituximab plus FAB group B4 chemotherapy: A Children's Oncology Group report. Brit J Haematol 2012; 159 (Suppl.) 1 (24).
- Osumi T, Mori T, Fujita N et al. Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group. Pediatr Blood Cancer 2016; 63 (10):1794-9.
- Minard-Colin V, Auperin A, Jourdain A et al. Outcome of relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in the Rituximab Era: A study of the Société Française des Cancers de l'Enfant. Brit J Haematol 2015; 171 Suppl. 1 (6).
- Awasthi A, Ayello J, van de Ven C et al. Obinutuzumab versus rituximab significantly enhances apoptosis and ADCC in vitro and overall survival in vivo of rituximab sensitive/resistant Burkitt Lymphoma (BL). Brit J Haematol 2015; 171 Suppl. 1 (83).
- Corongiu F, Mura R, Pillon M. Late effects of Rituximab in combination with chemotherapy in patients with Bcell NHL or BAL. Brit J Haematol 2015; 171 Suppl. 1 (66).
- Алескерова Г.А, Шервашидзе М.А., Попа А.В. и др. Результаты лечения острого лимфобластного лейкоза у детей по протоколу ALL IC-BFM 2002. Онкопедиатрия. 2016; 3 (4): 302-8.
- Gaynon P.S. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 2005; 131: 579-87.
- Koh K.N, Im H.J, Kim H et al. Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study. J Korean Med Sci 2017; 32 (4): 642-9. doi: 10.3346/jkms.2017.32.4.642.
- Bertaina A, Vinti L, Strocchio L et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol 2017; 176 (4): 629-36.
- Junk S, Cario G, Wittner N et al. Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines. Klin Padiatr 2015; 227 (3): 123-30.
- Franz D.N, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo - controlled phase 3 trial. Lancet 2013; 381 (9861): 125-32.
- Fouladi M, Laningham F, Wu J. Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 2007; 25 (30): 4806-12.
- Woessmann W, Seideman K, Mann G et al. The impact of methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood 2005; 105: 948-58.
- National Cancer Institute - Common Terminology Criteria for Adverse Events. CTCAE 2009. Version 4. https://www.calgb.org/Public/meetings/presentations/2009/ summer_ group/ cra_committee/04_ CTCAE-Chen_062009.pdf
- Miyamoto K.I, Kobayashi Y, Maeshima A.M et al. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Int J Hematol 2016; 103 (6): 693-702.
- Swerdlow S.H, Campo E, Lee Harris N et al. WHO Classification of Tumours of Haematopoetic and Lymphoid tissues. 4th Еd. International Agency for Research on Cancer. Lyon 2008; р. 439.
- Самочатова Е.В., Шелихова Л.Н., Белогурова М.Б. и др. Комбинированная химиоиммунотерапия больных неходжкинскими лимфомами из зрелых В-клеток возрастной группы до 18 лет: результаты многоцентрового исследования НХЛ 2004м с применением ритуксимаба и модифицированного протокола В-НХЛ БФМ 90. Онкогематология. 2009; 3: 4-14.